

SECTION 5 – 510(k) SUMMARY

Submitted by: DePuy Orthopaedics, Inc.
 700 Orthopaedic Drive
 Warsaw, IN 46581
 Phone: (305) 328-3851
 Fax: (305) 270-1382

NOV 07 2007

Contact Person: Suzana Otaño, Sr. Regulatory Affairs Associate

Date Prepared: August 28, 2007

Proprietary Name: Large Fragment Locking Plating System

Common Name: Plate, Fixation, Bone

Classification Name: Single/multiple component metallic bone fixation appliances and accessories (21 CFR § 888.3030)

Predicate Devices:

Synthes	K000682	Large Fragment Dynamic Compression Locking System
DePuy	K060969	POLYAX™ Locked Plating System

Intended Use: The Large Fragment Locking Plating System is intended for fixation of various long bones, such as the humerus, femur and tibia. It is also for use in fixation of osteopenic bone and fixation and stabilization of non-unions, malunions and osteotomies.

Technological Characteristics: The technological characteristics of the Large Fragment Locking Plating System are the same as the predicate devices including design and material.

Summary of Substantial Equivalence: The Large Fragment Locking Plating System is substantially equivalent to the currently marketed Synthes and DePuy devices. No new issues of safety or efficacy have been raised.



DEPARTMENT OF HEALTH & HUMAN SERVICES

Public Health Service

Food and Drug Administration
9200 Corporate Boulevard
Rockville MD 20850

NOV 07 2007

DePuy Orthopaedics, Inc.
% Ms. Suzana Otano
Sr. Regulatory Affairs Associate
700 Orthopaedic Drive
Warsaw, Indiana 46581

Re: K072423
Trade/Device Name: Large Fragment Locking Plating System
Regulation Number: 21 CFR 888.3030
Regulation Name: Single/multiple component metallic bone
fixation appliances and accessories
Regulatory Class: Class II
Product Code: HRS
Dated: October 8, 2007
Received: October 9, 2007

Dear Otano:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Center for Devices and Radiological Health's (CDRH's) Office of Compliance at (240) 276-0120. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). For questions regarding postmarket surveillance, please contact CDRH's Office of Surveillance and Biometric's (OSB's) Division of Postmarket Surveillance at (240) 276-3474. For questions regarding the reporting of device adverse events (Medical Device Reporting (MDR)), please contact the Division of Surveillance Systems at (240) 276-3464. You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at toll-free number (800) 638-2041 or (240) 276-3150 or the Internet address <http://www.fda.gov/cdrh/industry/support/index.html>.

Sincerely yours,

A handwritten signature in black ink, appearing to read "Mark N. Melkerson". The signature is fluid and cursive, with the first name "Mark" being the most prominent.

Mark N. Melkerson
Director
Division of General, Restorative
and Neurological Devices
Office of Device Evaluation
Center for Devices and
Radiological Health

Enclosure

SECTION 4 – INDICATIONS FOR USE STATEMENT

510(k) Number: K 072423

Device Name: **Large Fragment Locking Plating System**

Indications For Use: The Large Fragment Locking Plating System is intended for fixation of various long bones, such as the humerus, femur and tibia. It is also for use in fixation of osteopenic bone and fixation and stabilization of non-unions, malunions and osteotomies.

Prescription Use **X**
(Per 21 CFR 801 Subpart D)

AND/OR Over-the-Counter _____
(21 CFR 801 Subpart C)

(PLEASE DO NOT WRITE BELOW THIS LINE – CONTINUE ON ANOTHER PAGE IF NEEDED)

Concurrence of CDRH, Office of Device Evaluation (ODE)


(Division Sign-Off)

**Division of General, Restorative,
and Neurological Devices**

Page 1 of 1

510(k) Number K072423